ArticleBiology direct2026
Comprehensive multi-omics pan-cancer analysis revealed that ANTXR1 is a potential biomarker for diagnosis and immunotherapy.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAnthrax toxin receptor 1 (ANTXR1, TEM8) has been implicated in tumor angiogenesis and progression, yet its pan-cancer immunological role remains incompletely defined.
methodsWe conducted an integrative pan-cancer analysis using multi-omics and clinical data from TCGA, GTEx, and public databases to evaluate the expression, prognostic and diagnostic value, genomic features, immune associations, and drug sensitivity of ANTXR1. Single-cell and spatial transcriptomic analyses were performed to define its cellular and spatial distribution. Functional roles were validated in gastric cancer (GC) using in vitro and in vivo models.
resultsANTXR1 was aberrantly expressed across multiple tumor types and significantly associated with tumor stage and unfavorable prognosis, particularly in GC. Diagnostic analyses demonstrated high accuracy of ANTXR1 in several malignancies. Elevated ANTXR1 expression correlated with genomic instability, stromal enrichment, M2 macrophage infiltration, and reduced CD8⁺ T cell abundance, indicating an immunosuppressive tumor microenvironment. Single-cell and spatial analyses identified fibroblasts as the primary source of ANTXR1 with co-localization to extracellular matrix components. Functionally, ANTXR1 knockdown suppressed GC cells proliferation, migration, invasion, and tumor growth, inhibited M2 macrophage polarization, and enhanced CD8⁺ T cell activity, partly through PI3K/AKT pathway inhibition.
conclusionANTXR1 functions as a stromal-associated immunomodulatory driver of tumor progression and immune suppression, representing a promising biomarker and therapeutic target in stromal-rich cancers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.